Nivolumab Injection [Opdivo]

DRUG12 trials

Sponsors

Sheba Medical Center, Taris Biomedical LLC, Inge Marie Svane, Assistance Publique - Hôpitaux de Paris, Momotaro-Gene Inc.

Conditions

Advanced CancerAntineoplastic AgentsB Cell LymphomaBladder Cancer TNM Staging Distant Metastasis (M) M0Bladder Cancer TNM Staging Primary Tumor (T) T2Bladder Cancer TNM Staging Primary Tumor (T) T2ABladder Cancer TNM Staging Primary Tumor (T) T2BBladder Cancer TNM Staging Primary Tumor (T) T3

Phase 1

Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer

CompletedNCT03507699

Sheba Medical CenterColorectal Neoplasms Malignant, Liver Metastases

Start: 2018-12-15End: 2022-05-25Updated: 2023-04-18

Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

TerminatedNCT03518320

Taris Biomedical LLCBladder Cancer TNM Staging Distant Metastasis (M) M0, Bladder Cancer TNM Staging Primary Tumor (T) T2, Bladder Cancer TNM Staging Primary Tumor (T) T2A +6

Start: 2019-01-02End: 2019-12-11Updated: 2024-08-27

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Active, not recruitingNCT04396821

Suzhou Transcenta Therapeutics Co., Ltd.Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer +1

Start: 2020-05-28End: 2026-11-30Target: 150Updated: 2025-12-17

Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors

RecruitingNCT05266612

Virogin Biotech Canada LtdSolid Tumor

Start: 2022-11-09End: 2025-12-31Target: 12Updated: 2024-08-09

Phase 2

Melanoma Metastasized to the Brain and Steroids

RecruitingNCT03563729

Inge Marie SvaneMalignant Melanoma

Start: 2018-06-06End: 2028-06-06Target: 80Updated: 2023-07-13

Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation

CompletedNCT03630640

Assistance Publique - Hôpitaux de ParisHepatocellular Carcinoma

Start: 2018-10-11End: 2023-08-19Updated: 2024-07-31

MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma

Momotaro-Gene Inc.Malignant Pleural Mesothelioma

Start: 2019-08-15End: 2023-01-01Updated: 2022-06-16

An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

RecruitingNCT05223816

Virogin Biotech Canada LtdHepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma

Start: 2024-01-24End: 2025-12-31Target: 97Updated: 2024-08-09

CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma

RecruitingNCT05257590

TaiRx, Inc.Advanced Cancer, Hepatocellular Carcinoma

Start: 2022-05-23End: 2026-03-31Target: 95Updated: 2025-12-17

Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion

Tel-Aviv Sourasky Medical CenterB Cell Lymphoma

Start: 2022-05-11End: 2024-10-31Target: 20Updated: 2022-05-26

Checkpoint Inhibitors and SBRT for MCRPC

CompletedNCT05655715

Herlev and Gentofte HospitalCastrate Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Prostate Cancer Metastatic +1

Start: 2019-11-25End: 2024-08-30Updated: 2024-10-16

Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma

RecruitingNCT05964101

The First Affiliated Hospital of Guangzhou Medical UniversityAntineoplastic Agents, Carcinoma, Squamous, Neoplasms

Start: 2023-10-01End: 2026-05-31Target: 25Updated: 2024-05-21

Related Papers

CA209-8TY trial, a randomized phase 2 trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in metastatic castration-resistant prostate cancer.

Journal of Clinical Oncology2025-05-28

Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study.

2024-10-113 citations

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Journal of Clinical Oncology2024-08-101 citations

CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.

Journal of Clinical Oncology2024-06-011 citations

Abstract CT132: A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors

Cancer Research2024-04-055 citations

Oncolytic virotherapy stimulates anti‑tumor immune response and demonstrates activity in advanced sarcoma: Report of two cases

Oncology Letters2024-04-032 citations

Abstract 3629: Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials

Cancer Research2024-03-22

A multi-cohort phase I/IIa clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 administered as a monotherapy, with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors: TransStar101.

Journal of Clinical Oncology2023-06-014 citations

The initial report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors.

Journal of Clinical Oncology2023-06-012 citations

Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma.

Journal of Clinical Oncology2023-01-243 citations

TST001 (a high affinity humanized anti-claudin18.2 monoclonal antibody) in combination with nivolumab plus capecitabine and oxaliplatin as first-line or with nivolumab as late-line treatment in locally advanced and metastatic gastric/gastroesophageal junction (G/GEJ) cancer: Design of cohorts from a phase I/IIa study (TST001-1002).

Journal of Clinical Oncology2023-01-243 citations

Randomised phase II trial of stereotactic body radiotherapy in combination with<b>check</b>point inhibitors in metastatic castration-resistant<b>pro</b>state cancer (CheckPRO): a study protocol

BMJ Open2023-01-013 citations

A phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of TST001 in patients with locally advanced or metastatic solid tumors.

Journal of Clinical Oncology2022-01-195 citations